MTM(688029) 国泰君安·2024-11-01 06:42Investment Rating - Maintains an "Overweight" rating with a target price of RMB 92.25, up from the previous target of RMB 76.51 [4] Core Views - Domestic growth is under pressure due to centralized procurement, but dealer inventory has normalized, indicating potential for future growth [2][3] - Overseas markets continue to grow rapidly, with strong performance in Asia-Pacific, Americas, and EMEA regions [3] - New products are receiving positive feedback, supporting the company's growth trajectory [2][3] Financial Performance - Q3 2024 revenue reached RMB 679 million, a 13.44% YoY increase, with net profit attributable to shareholders at RMB 141 million, up 15.06% YoY [3] - Domestic revenue in Q3 2024 was RMB 323 million, a 2% YoY decline, while overseas revenue grew 27% YoY to RMB 350 million [3] - Gross margin improved to 67.06%, up 2.44 percentage points YoY, driven by automation and cost optimization [3] Market and Product Development - The company has expanded its presence in the US, covering over 500 hospitals and 1,000 outpatient surgery centers, with a current market share of around 5% [3] - In Europe, the company is strengthening its direct sales channels and has signed a merger agreement with CME, which has a comprehensive sales network across Europe [3] - Visualized products are performing well, with over 750 hospital installations in the first three quarters of 2024, compared to nearly 500 in 2023 [3] Financial Forecasts - EPS forecasts for 2024-2026 have been revised to RMB 3.07, RMB 3.69, and RMB 4.36, down from previous estimates of RMB 3.21, RMB 3.92, and RMB 4.77 [3] - Revenue is expected to grow to RMB 2.755 billion in 2024, RMB 3.221 billion in 2025, and RMB 3.732 billion in 2026 [10] - Net profit attributable to shareholders is projected to reach RMB 577 million in 2024, RMB 694 million in 2025, and RMB 820 million in 2026 [10] Valuation and Market Data - The company's market capitalization is RMB 13.6 billion, with a current stock price of RMB 72.40 [5] - The stock has a 52-week price range of RMB 56.60 to RMB 98.82 [5] - The company's P/E ratio is expected to decrease from 23.57 in 2024 to 16.59 in 2026 [10]